GKB Ophthalmics Ltd has submitted an insider trading disclosure to the Bombay Stock Exchange, reporting share acquisitions by a promoter group entity. The disclosure was filed on December 30, 2025, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Transaction Details

Krishna Gopal Gupta & Sons (HUF), a promoter group entity, purchased equity shares of GKB Ophthalmics through market transactions between November 20 and December 10, 2025. The following table summarizes the key transaction parameters:

Regulatory Compliance

The company noted that while the transaction value did not exceed the threshold limit prescribed under Regulation 7(2) of SEBI's Prohibition of Insider Trading Regulations, 2015, the disclosure was filed as a good corporate governance measure. The filing was made pursuant to Regulation 7(2) read with Regulation 6(2) of the PIT Regulations, 2015.

Shareholding Changes

According to the detailed disclosure form, Krishna Gopal Gupta & Sons (HUF) executed multiple transactions during the specified period. The entity's shareholding increased through several purchases:

• Initial holding: 296,141 shares (5.87%)
• Final holding after all transactions: 300,053 shares (5.94%)
• Net increase: 3,912 shares

Corporate Governance Commitments

K.G. Gupta, Karta of Krishna Gopal Gupta & Sons HUF, provided undertakings as part of the disclosure process. The entity committed to preserve transaction proofs and payment details for three years from the transaction date and agreed to hold the acquired securities for a minimum period of six months. Any urgent sale within this period would require prior approval from the company's Compliance Officer.

Company Information

GKB Ophthalmics Ltd, incorporated with CIN L26109GA1981PLC000469, operates from its facility at Tivim Industrial Estate, Mapusa, Goa. The company's shares trade on BSE under scrip code 533212 with ISIN INE265D01015. Company Secretary Pooja Bicholkar signed the disclosure filing on behalf of the company.

GKB Ophthalmics Limited shareholders have passed resolutions through postal ballot on November 1, 2025, approving the voluntary winding up of material subsidiary GSV Ophthalmics Private Limited and related party transactions worth Rs. 15.00 crores.

GKB Ophthalmics Ltd. sought shareholder approval for two key resolutions through a remote e-voting process, which concluded on November 1, 2025.

Voting Results

The voting results, as reported by the scrutinizer, Shivaram Bhat, show mixed outcomes for the two resolutions:

Key Points

1. Voting Process: The e-voting period ran from October 3, 2025, to November 1, 2025, with 2,658 shareholders eligible to vote as of the record date (September 26, 2025).

2. Shareholder Correction: One shareholder holding 134,218 shares requested a correction of their vote on Resolution 1 from dissent to assent, citing an inadvertent error. The company accommodated this request, considering these votes in favor of the resolution.

3. Resolution Outcomes:

   • The first resolution, seeking approval for the Related Party Transaction related to winding up, did not pass despite the vote correction.
   • The second resolution for the voluntary winding up of GSV Ophthalmics Private Limited passed with an overwhelming majority.

4. Regulatory Compliance: The company conducted the postal ballot in accordance with Section 110 of the Companies Act, 2013, and SEBI regulations.

Implications

The approval of the voluntary winding up of GSV Ophthalmics Private Limited indicates shareholder support for this decision. The subsidiary, which holds the company's Rs. 11.70 crores investment, never commenced operations since inception due to COVID-19 disruptions, making the project financially unviable.

Despite the approval for winding up, the rejection of the first resolution suggests potential complications in executing this decision, as it relates to the approval of related party transactions necessary for the winding-up process.

GKB Ophthalmics' management may need to reassess their approach to the winding-up process in light of these voting results. The company might consider engaging with shareholders to address concerns related to the related party transaction aspects of the winding-up procedure.

The proceeds from the winding up are expected to be used for general corporate purposes.

As this corporate action unfolds, stakeholders will be watching closely to see how GKB Ophthalmics navigates the path forward for its material subsidiary, GSV Ophthalmics Private Limited, in light of these shareholder decisions.